|
CLINICAL TRIAL |
DATE
ENROLL ENDS |
|
ARIES
–1 Ambrisentan in PAH- A Phase III, Randomized, Double-Blind,
Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects
with Pulmonary Arterial Hypertension
|
Start
9/03
Ends
– when MYOGEN, INC reaches desired enrollment numbers
|
|
ARIES-EX
– An extension to the ARIES –1 study for subjects who are benefiting from
Ambrisentan |
Same
as ARIES -1 |
Pfizer
A148-1141
A
Multicenter, multinational, randomized, double-blind, placebo controlled,
parallel group study to assess the safety and efficacy of a subject optimized
dose of Sildenafil (20, 40, and 80mg Sildenafil) TID based on toleration,
when used in combination with intravenous Prostacyclin (Epoprostenol, Flolan)
in the treatment of pulmonary arterial hypertension |
Start
2003-
When
Pfizer reaches desired enrollment numbers |
3.
Pfizer Extension study A148-1153
Subjects
allowed to roll over into Extension study if showing improvement with
medication. |
Same
as Pfizer A148-1141 |
INOT32c—INO
Therapeutics sponsor
Dose
Response of Pulsed Nitric Oxide in Adults with COPD Requiring Long-Term
Oxygen Therapy |
Starting
September 19,2005 |
|
INOT33—Extension
study to INOT32c |
Same
as above, |
REVEAL
– Sponsor United Therapeutics
Study
for site pain, for subjects using Remodulin sub-cutaneously |
Start
6/24/04
Ends
when desired enrollment is reached. |
AMB 222—Sponsor
Myogen,
Inc
Study
for subjects who have failed treatment with Bosentan due to elevated LFT’s |
Start
4/2005
Ends: When sponsor reaches desired enrollment |
|
Flolan
to Remodulin Transition Study
Sponsor:
Dr. Nicholas HillNew
Eng Med Center Hosp, Boston, MA
|
Start
6/03
Ends
When sponsor, Dr. Nicholas Hill reaches desired enrollment |
Flolan
to Tracleer
Sponsor:
Dr. Nicholas Hill
New
Eng Med Center Hospital, Boston, MA |
Start 6/03
Ends
when sponsor reaches desired enrollment
|
|
A
Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the
Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil (Cialis) in the Treatment
of patients with Pulmonary Arterial Hypertension |
Start:
Oct-Nov/2005
Stop
Nov/2006 |
|
Extension
study for Tadalafil (Cialis) |
Start
Oct-Nov /2005
Stop:
ongoing X 2 years
|
|
Iloprost
in post-operative cardiothoracic patients who have pulmonary hypertension |
Start
Oct-Nov/2005
Stop
Nov /2006
|
